Regional Advisor

**Location**: Brussels

**Contract**: permanent, 100%

**Starting date**: As soon as possible, no later than mid-June 2025

**Deadline to apply**: 08.05.2025

**I. MSF INTERNATIONAL**

Médecins Sans Frontières (MSF) is an international, independent, medical humanitarian organisation that delivers emergency aid to people affected by armed conflict, epidemics, healthcare exclusion and natural disasters. MSF assists people based only on need and irrespective of race, religion, gender or political affiliation.

MSF International is the legal entity that binds MSF’s 24 sections, 27 associations and 18 branch offices together. Registered in Switzerland, MSF International provides coordination, information and support to the MSF Movement, as well as implements international projects and initiatives as requested.

The job’s description may evolve according to the new MSF Access Strategic Plan 2026-2031 and the evolution of some dossiers to stand-still or completion. Its main parameters (scope, area of expertise) would not be essentially altered. Until that key stage, the incumbent is expected to demonstrate a degree of flexibility in the performance of her/his work.

**II. POSITION BACKGROUND**

MSF Access (previously “Access to Products for Healthcare” (APH)) is the new structure which was created after a restructuration of the MSF Access Campaign (AC). It refers to advocating and involving into policy making to increase accessibility, availability, affordability, appropriateness, and quality of products for healthcare for the populations MSF assists and their communities.

Most of the structure’s staff will be based in five regional hubs:

- Dakar, Senegal: covering West and Central Africa
- Rio de Janeiro, Brazil: covering the Americas
- Kuala Lumpur, Malaysia: covering Asia and Oceania
- Nairobi, Kenya: covering Eastern and Southern Africa
- Brussels, Belgium: covering Europe, the Middle East, and Northern Africa (MENA)

The new structure has the following responsibilities:

- Gather input for MSF’s Common Priorities (CP) on Access to Health Products (Access).
- Design and implement Access Analysis & Advocacy to respond to the agreed CP.
- Provide, facilitate, support on Access files outside the CP to MSF entities that request it.
- Maintain an overview of Access initiatives across MSF and report on them annually.
- Research, and stay informed of, the Access landscape globally and regionally to inform the MSF Movement of opportunities and threats.

**III. PLACE IN THE ORGANIZATION**

The Regional Advisor - Europe will report to the Regional Access Coordinator for Europe & MENA. S/He will work in close cooperation with the Access Heads of Advocacy and Analysis, the Regional Advisor - Europe contributes to furthering the regional context understanding, maintaining and expanding key networks and engagement with relevant stakeholders to support the design and implementation of effective advocacy strategies towards governments, non-governmental stakeholders, pharmaceutical companies, and the research community in Europe in support of MSF’s strategic objectives in the region and globally.

For 2025 and probably also extending in the following years the MSF Access hub for Europe will be geared towards a sustained focus & involvement on following fields:

- Access to Tuberculosis (TB) treatments in the EU region. Through its medical work in Europe, MSF has been confronted with a lack of access to both WHO-recommended and internationally used drug-sensitive and drug-resistant TB treatments. Regulatory barriers, high prices and failed market dynamics prevent patients in most European countries to benefit from these protocols.
- Antimicrobial resistance: AMR is a growing global threat, being the leading cause of death worldwide. Recent estimates show the threat is growing at alarming rates. Europe can have a leading role in prioritizing R&D and investments to create the conditions for an equitable & affordable access to antimicrobials in LMIC.
- Pandemic preparedness and response (PPR): While a final round of negotiations was hold in April 2025, to enhance global systems for preventing, preparing for, and responding to pandemics and other health emergencies, MSF will have to remain closely following how these will be translated in future responses. MSF emphasizes that effective PPR initiatives must address structural determinants of inequitable access to medical products.
- Vaccinations: Immunisation is one of the most effective and cost-efficient public health interventions. GAVI, the Vaccine Alliance, which was set up to increase access to vaccines for children living in low
- and middle-income countries (LMIC) has seen recently a dramatic cut of its budget by the US withdrawal. This impact will likely be compounded by other donors’ budget cuts. The EU and some European Member States being active Board Members of the Alliance are therefore important stakeholders to be dealt with.
- Diabetes: Overall diabetes prevalence